All In Biotech

Drug Trial Radar · NCT07471139

SWITCH: Apixaban vs Vitamin K in HM3

The SWITCH Trial: A Randomized Controlled Study of Apixaban Versus Vitamin K Antagonists in Patients With HeartMate 3 Left Ventricular Assist Devices

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Aug 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.

Conditions

  • LVAD (Left Ventricular Assist Device) Thrombosis
  • Heart Failure
  • Bleeding
  • Thrombosis; Artery
  • Stroke
  • Heart Transplant

Interventions

  • WarfarinDrug

    Warfarin dose titrated for an International Normalized Ratio (INR) \>= 1.8

  • ApixabanDrug

    Apixaban 5 mg bid (twice a day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival free of major hemocompatibility related adverse eventTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.